As the use of AI spreads through every industry and becomes more of a part of our lives every day, researchers are also ...

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced that the U.S. Food and Drug Administration (FDA) ...

BioMarin Pharmaceutical’s third quarter results reflected steady top-line growth, with management highlighting enzyme ...

In poultry houses where broiler chickens—birds bred and raised specifically for meat production—are grown, feed is delivered ...

Producers can achieve these products on a commercial scale without the demands of the traditional fermentation process.

Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...

Q3 2025 Earnings Call Transcript October 27, 2025 BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS ...

Roughly 25% to 50% of the total commercial nitrogen applied to fields across the state occurs in the fall. Waiting for cooler ...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today ...

Hansa Biopharma AB ( ($SE:HNSA) ) has issued an announcement. Hansa Biopharma has increased its registered share capital and the number of shares ...

LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutrac ...

Japan's Ministry of Health, Labor and Welfare (MHLW) has granted orphan regenerative medicine product designation to Kyowa ...